Due to health issues, this site is no longer maintained and will be shut down shortly.

GANX Gain Therapeutics, Inc.

Gain Therapeutics is redefining drug discovery with its See-Tx target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding.

$4.90  +0.06 (1.24%)
As of 03/24/2023 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/18/2021
Outstanding shares:  11,883,368
Average volume:  62,348
Market cap:   $57,515,501
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy